# Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Study · id `cardio:ct-nct02517866` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02517866](<https://clinicaltrials.gov/study/NCT02517866>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02517866

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

## Technical summary

Registry record NCT02517866. Allocation not applicable; no masking; primary purpose treatment. Start 2015-07-13 (actual); primary completion 2016-11-15 (actual). Results posted on 2019-03-01.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 380 participants (enrolled count; ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Started: 2015-07-13 (actual) (ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Primary completion: 2016-11-15 (actual) (ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Completion: 2016-11-25 (actual) (ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Results first posted: 2019-03-01 (ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Countries: China; Taiwan; Thailand (ClinicalTrials.gov record NCT02517866, source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02517866-2019-03-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
- Condition: Essential Hypertension
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Azilsartan Medoxomil
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 319a5d0c4cf4f9297fd3ea4e38d7dce3867135211b9aaee0969f61b2d41b649a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
